Anonymousabout 2 hours ago
The CDC reported in April 2026 that extensively drug-resistant (XDR) Shigella infections rose from 0% of tested isolates in 2011 to 8.5% in 2023, with no FDA-approved oral treatments available. The 510 confirmed XDR cases — 84% of which emerged in 2022-2023 alone — disproportionately affect adult men, people experiencing homelessness, and those living with HIV, raising questions about surveillance gaps, flat federal funding, and whether the public health system can contain a pathogen that spreads easily and transfers its resistance genes to other bacteria.